A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

被引：25
|
作者：
Thondam, S. K. [1 ]
Cuthbertson, D. J. [1 ]
Aditya, B. S. [1 ]
MacFarlane, I. A. [1 ]
Wilding, J. P. [1 ]
Daousi, C. [1 ]
机构：
[1] Univ Liverpool, Dept Obes & Endocrinol, Aintree Univ Hosp NHS Fdn Trust Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
CLINICAL ENDOCRINOLOGY | 2012年 / 77卷 / 04期
关键词：
FOOD-INTAKE; WEIGHT; HUMANS; DAMAGE;
D O I：
10.1111/j.1365-2265.2012.04368.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [41] Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
    Babenko, Alina Yu.
    Savitskaya, Daria A.
    Kononova, Yulia A.
    Trofimova, Aleksandra Yu.
    Simanenkova, Anna V.
    Vasilyeva, Elena Yu.
    Shlyakhto, Evgeny V.
    JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [42] Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States
    Xu, Yunwen
    Tcheugui, Justin B. Echouffo
    Coresh, Josef
    Grams, Morgan E.
    Selvin, Elizabeth
    Fang, Michael
    Shin, Jung-Im
    DIABETES OBESITY & METABOLISM, 2025,
  • [43] From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer
    Alhajahjeh, Abdulrahman
    Al-Faouri, Raad
    Bahmad, Hisham F.
    Bader, Taima'
    Dobbs, Ryan W.
    Abdulelah, Ahmed A.
    Abou-Kheir, Wassim
    Davicioni, Elai
    Lee, David I.
    Shahait, Mohammed
    CANCERS, 2024, 16 (08)
  • [44] Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    Nauck, M. A.
    Vardarli, I.
    Deacon, C. F.
    Holst, J. J.
    Meier, J. J.
    DIABETOLOGIA, 2011, 54 (01) : 10 - 18
  • [45] Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor
    Helmstaedter, Johanna
    Keppeler, Karin
    Kuester, Leonie
    Muenzel, Thomas
    Daiber, Andreas
    Steven, Sebastian
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 659 - 676
  • [46] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
    Parab, Panah
    Chaudhary, Priti
    Mukhtar, Sonia
    Moradi, Ali
    Kodali, Athri
    Okoye, Chiugo
    Klein, Dhadon
    Mohamoud, Iman
    Olanisa, Olawale O.
    Hamid, Pousette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [47] Glucagon-like peptide-1 (GLP-1) levels in obese patients with and without type 2 diabetes.
    Mannucci, E
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Ciani, S
    Messeri, G
    Rotella, CM
    DIABETOLOGIA, 2000, 43 : A146 - A146
  • [48] CJC-1131 -: Agent for type 2 diabetes glucagon-like peptide-1 (GLP-1) analogue
    Davies, SJ
    Martín, L
    Castañer, RM
    DRUGS OF THE FUTURE, 2005, 30 (06) : 553 - 557
  • [49] Modern possibilities of pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1)
    Shestakova, M., V
    Vikulova, O. K.
    DIABETES MELLITUS, 2007, 10 (01): : 9 - 15
  • [50] Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    M. A. Nauck
    I. Vardarli
    C. F. Deacon
    J. J. Holst
    J. J. Meier
    Diabetologia, 2011, 54 : 10 - 18
12345